slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 70,711-70,740
Pages 3,679
Rows per page 30
Component
70,711-70,740 of 110,355
02
Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slidesAeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank Beat · Situation & Context1 hit
06
Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slidesAeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank Beat · Problem & Complication1 hit
07
The chart uses a conceptual scatter plot to contrast current SOC with a future target state, emphasizing the need for higher efficacy and better convenience.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank Beat · Problem & Complication1 hit
10
The slide uses a visual metaphor of two antibodies merging into a single complex to represent combination therapy.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank Beat · Solution & ApproachLoop · Golden Circle1 hit
12
The slide uses a Gantt-style visualization to show the progression of various drug programs (SPY001-SPY230).Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank Beat · Solution & ApproachLoop · Golden Circle1 hit
14
Includes a testimonial quote from a US KOL.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
15
The chart uses a vertical axis to categorize drugs by mechanism of action (α4β7, IL-23s, TNFαs, S1P1s, JAKs) and a horizontal axis for efficacy (Pbo-adjusted clinical remission %).Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
19
The chart shows dose-response curves for cell binding. The table summarizes EC50 values.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
20
The chart shows a biphasic exponential decay curve for three datasets.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
21
The chart uses a regression line to correlate human and NHP half-lives, highlighting the 3.1x multiplier for YTE-modified antibodies.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
22
The slide uses a visual timeline/comparison to contrast the high injection frequency of the competitor with the lower frequency of SPY001.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
23
The chart combines a bar chart of competitor benchmarks with a bar chart showing vedolizumab's exposure-response quartiles.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
24
Data from GEMINI 1 study; compares Q8W and Q4W dosing regimens.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
26
The slide uses a dual-axis approach: a bar chart for valuation benchmarks and a timeline for clinical milestones.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
28
The chart compares clinical remission rates across different drug classes (TL1A, a4b7, IL-23s, TNFas, S1P1s, JAKs) with a safety gradient indicated on the Y-axis.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
29
Uses a checkmark matrix to highlight competitive advantages of SPY002.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
31
The slide uses a bar chart to compare efficacy and provides a strategic rationale for pursuing both monomeric/trimeric and trimeric-only approaches.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
33
The table contrasts established drugs (with confirmed exposure-response) against newer anti-TL1A agents (PRA023, RVT-3101) where this relationship is currently TBD.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
38
The slide uses a bar chart to illustrate additive clinical remission rates, with a table below providing additional clinical metrics (N, maintenance remission, safety).Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
40
Includes a specific note that this is an 'Illustrative example' and 'Preliminary; pending regulatory feedback'.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
43
The slide uses a comparative bar chart structure to show the delta in efficacy when using a companion diagnostic (CDx).Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
47
The table uses a custom visualization for market cap range (min, IPO, today, max) and clinical stage progression.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
48
The table maps historical industry M&A deals to Spyre's internal pipeline development milestones (2025-2027).Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
02
a.k.a. Brands | Investor Presentation Deck | 13 slidesa.k.a. Brands | Investor Presentation Deck | 13 slides · a.k.a. Brands
Pitch deck Investor relations Beat · ProblemLoop · Why Now1 hit
07
Includes a source note for the 'Top 10 fashion website' claim.a.k.a. Brands | Investor Presentation Deck | 13 slides · a.k.a. Brands
Pitch deck Investor relations Beat · Market Size1 hit
04
Alkermes | Investor Presentation Deck | 56 slidesAlkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Current Reality (Pain)1 hit
05
This is a classic 'preempt_rebuttal' style slide used in proxy contests to defend the incumbent board.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Current Reality (Pain)1 hit
07
The slide uses a four-column layout to summarize key business pillars.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Current Reality (Pain)1 hit
08
The slide uses a three-column layout to present strategic priorities, with a footer highlighting stock performance relative to peers.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Future Vision (Gain)1 hit
10
The slide uses a numbered list format to map strategic pillars to specific results.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Future Vision (Gain)Loop · Before After1 hit